Morand EF - Search Results

1

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.

Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, Morand EF. Tummala R, et al. Among authors: morand ef. Lupus Sci Med. 2021 Feb;8(1):e000464. doi: 10.1136/lupus-2020-000464. Lupus Sci Med. 2021. PMID: 33597205 Free PMC article. Clinical Trial.

2

Fibromyalgia syndrome and disease activity in systemic lupus erythematosus.

Morand EF, Miller MH, Whittingham S, Littlejohn GO. Morand EF, et al. Lupus. 1994 Jun;3(3):187-91. doi: 10.1177/096120339400300310. Lupus. 1994. PMID: 7951304

3

Methotrexate use in systemic lupus erythematosus.

Kipen Y, Littlejohn GO, Morand EF. Kipen Y, et al. Among authors: morand ef. Lupus. 1997;6(4):385-9. doi: 10.1177/096120339700600407. Lupus. 1997. PMID: 9175024 Clinical Trial.

4

Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement.

Cheng Q, Hoi A, Hickey MJ, Morand EF. Cheng Q, et al. Among authors: morand ef. Lupus. 2012 May;21(6):632-41. doi: 10.1177/0961203312436860. Epub 2012 Feb 16. Lupus. 2012. PMID: 22345121

5

Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic.

Golder V, Connelly K, Staples M, Morand E, Hoi A. Golder V, et al. Lupus. 2013 Nov;22(13):1425-30. doi: 10.1177/0961203313500547. Epub 2013 Aug 13. Lupus. 2013. PMID: 23942610

6

Validation of the Lupus Impact Tracker in an Australian patient cohort.

Antony A, Kandane-Rathnayake RK, Ko T, Boulos D, Hoi AY, Jolly M, Morand EF. Antony A, et al. Among authors: morand ef. Lupus. 2017 Jan;26(1):98-105. doi: 10.1177/0961203316664593. Epub 2016 Aug 11. Lupus. 2017. PMID: 27516435

7

Independent association of glucocorticoids with damage accrual in SLE.

Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, Hoi A, Nikpour M, Morand EF. Apostolopoulos D, et al. Among authors: morand ef. Lupus Sci Med. 2016 Nov 22;3(1):e000157. doi: 10.1136/lupus-2016-000157. eCollection 2016. Lupus Sci Med. 2016. PMID: 27933196 Free PMC article.

8

Discordance of patient and physician health status concerns in systemic lupus erythematosus.

Golder V, Ooi JJY, Antony AS, Ko T, Morton S, Kandane-Rathnayake R, Morand EF, Hoi AY. Golder V, et al. Among authors: morand ef. Lupus. 2018 Mar;27(3):501-506. doi: 10.1177/0961203317722412. Epub 2017 Aug 1. Lupus. 2018. PMID: 28764617

9

Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?

Boulos D, Koelmeyer RL, Morand EF, Hoi AY. Boulos D, et al. Among authors: morand ef. Lupus Sci Med. 2017 Jul 28;4(1):e000212. doi: 10.1136/lupus-2017-000212. eCollection 2017. Lupus Sci Med. 2017. PMID: 29214035 Free PMC article.

10

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R. Morand EF, et al. Ann Rheum Dis. 2018 May;77(5):706-713. doi: 10.1136/annrheumdis-2017-212504. Epub 2018 Feb 2. Ann Rheum Dis. 2018. PMID: 29420200 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

336 results

Search Page

Filters